ClinicalTrials.gg
Not yet recruitingNCT07389304SBBU/IRC-25-31Updated Feb 5, 2026

[Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]

A Phase 1 interventional study of Rosuvastatin (5mg, 20mg, 40mg) and Atorvastatin (10mg, 20mg, 40mg) in Lipid Profile,Blood Pressure, sponsored by Shaheed Benazir Bhutto University Sheringal Dir Upper. Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Shaheed Benazir Bhutto University Sheringal Dir Upper · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

This study is a Phase I randomized clinical trial aiming to investigate the short-term effects of three commonly prescribed statins i.e (Atorvastatin, Rosuvastatin, and Simvastatin) at different dose levels i.e lo,median and high doses on cardiovascular parameters i.e Blood pressure and ECG morphology in healthy volunteers. The study will assess changes in blood pressure and ECG morphology following two days of statin administration under controlled conditions.

Read the detailed description

The goal of this study is to evaluate the effects of these three statins on the cardiovascular parameters in a dose-dependent manner. In this Phase 1 clinical trial we will enroll healthy volunteers who will be randomized to receive one of three statins at low, moderate, or high doses for two days. .

02

Conditions studied

  • Lipid Profile,Blood Pressure

Keywords

  • sBlood Pressure,ECG change
03

In context

Lead sponsor

Shaheed Benazir Bhutto University Sheringal Dir Upper is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers
  • Normal
  • Normal Blood Pressure
  • Normal lipid levels

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of diabetes mellitus,BP
  • With chronic diseases e.g heart disease, kidney disease
  • ≥450 ms (men) or ≥470 ms (women)
  • changes
  • Electrolyte imbalance,
  • Participants taking other medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Rosuvastatin (5mg, 20mg, 40mg)

    The assigned participants will be given Rosuvastatin 5mg, 20mg, 40mg OD for two days

    Drug: Rosuvastatin (5mg, 20mg, 40mg)

  • Experimental
    Atorvastatin (10mg,20mg, 40mg)

    The assigned participants will be given Atorvastatin 10mg,20mg, 40mg OD for two days

    Drug: Atorvastatin (10mg, 20mg, 40mg)

  • Experimental
    Simvastatin (10mg, 20mg, 40mg)

    The assigned participants will be given Simvastatin 10mg, 20mg, 40mg OD for two days

    Drug: Simvastatin (10mg, 20mg, 40m

Interventions

  • DrugRosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The Rosuvastatin (5mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The Atorvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

  • DrugSimvastatinStudies of SimvastatinSimvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The Simvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

06

What researchers measure

Primary outcomes

  1. Blood Pressure Measurements

    Blood Pressure of the subjects will be determined by sphygmomanometer

    Time frame: before dosing and 2 days after dosing achieving peak plasma concentrations respectively]

Secondary outcomes

  1. Electrocardiograms (ECGs) Measurements

    ECGs of the subjects will be determined by 12 Leads ECG Machine.QT interval and QRS complex in milliseconds will be analyzed to determine the effects of these statins on ECG morphology

    Time frame: before dosing and 2 days after dosing achieving peak plasma concentrations respectively]

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The study results will be shared in well reputable Journals without the participant identifiers

Supporting information: Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Feb 5, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Feb 20, 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07389304
Lead sponsor
Shaheed Benazir Bhutto University Sheringal Dir Upper
Collaborators
Khyber Medical University Peshawar
Responsible party
Dr Abid Ullah (Lecturer, Shaheed Benazir Bhutto University Sheringal Dir Upper) — Principal investigator
First posted
Feb 5, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Feb 20, 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Dr Abid Ullah, Ph.D
Contact
abid@sbbu.edu.pk
09448850 ext. 527

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Atorvastatin · Simvastatin

Start the discussion